On the trail of a cognitive enhancer for the treatment of schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 29, Issue 2, 2005, Pages 219-232

  Stip, Emmanuel ^a   Chouinard, Sylvie ^a   Boulay, Luc Jean ^a,b  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

Cholinergic system; Cognition; Cognitive enhancer; Neuroleptic; Schizophrenia

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; CHLORPROMAZINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; FLUPHENAZINE; GLYCINE; GUANFACINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT; OLANZAPINE; PHYSOSTIGMINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ATTENTION; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COGNITION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; HUMAN; LEARNING; MEMORY; MEMORY DISORDER; MOTOR ACTIVITY; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; VERBAL MEMORY; VISION; WORKING MEMORY;

EID: 13444283738     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.11.004     Document Type: Review

References (127)

1. J. Addington, D. Addington, and L. Gasbarre Distractibility and symptoms in schizophrenia J. Psychiatry Neurosci. 22 1997 180 184
2. G.K. Aghajanan, and G.J. Marek Serotonin model of schizophrenia: emerging role of glutamate mechanisms Brain Res. Rev. 31 2000 302 312
3. A.F. Arnsten Adrenergic targets for the treatment of cognitive deficits in schizophrenia Psychopharmacology (Berl.) 174 2004 25 31
4. C.M. Beasley Jr., G.D. Tollefson, and P.V. Tran Efficacy of olanzapine: an overview of pivotal clinical trials J. Clin. Psychiatry 58 1997 7 12 (Suppl.)
5. R.M. Bilder, R.S. Goldman, J. Volavka, P. Czobor, M. Hoptman, B. Sheitman, J.P. Lindermayer, L. Citrome, J. McEvoy, M. Kunz, M. Chakos, T.B. Cooper, T.L. Horowitz, and J.A. Lieberman Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder Am. J. Psychiatry 159 2002 1018 1028
6. T.A. Blaxton, C. Myers, A. Kakoyannis, O. Robles, J.D. Sherr, and G.K. Thaker Effects of nicotine on memory in schizophrenic patients Schizophr. Res. 49 2001 127
7. J. Brandt The Hopkins verbal learning test: development of a new verbal memory test with six equivalent forms Clin. Neuropsychol. 5 1991 125 142
8. C.R. Breese, M. Lee, C.E. Adams, B. Sullivan, J. Logel, K.M. Gillen, M.J. Marks, A.C. Collins, and S. Leonard Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia Neuropsychopharmacology 23 2000 351 364
9. R.W. Buchanan, C. Holstein, and A. Breier The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance Biol. Psychiatry 36 1994 717 725
10. M.H. Chakos, J.A. Lieberman, J. Alvir, R. Bilder, and M. Ashtari Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine Lancet 345 1995 456 457
11. W.J. Chen, S.K. Liu, C.J. Chang, Y.J. Lien, Y.H. Chang, and H.G. Hwu Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients Am. J. Psychiatry 155 1998 1214 1220
12. S. Chouinard, E. Stip, J. Poulin, R. Godbout, F. Guillem, and H. Cohen Rivastigmine effects on procedural memory and attention in patients with schizophrenia: preliminary results Schizophr. Res. 67 2004 269 270
13. W. Classen, and G. Laux Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine Pharmacopsychiatry 21 1988 295 297
14. B. Cornblatt, R.S. Kern, W.H. Carson, E. Stock, M. Ali, G. Ingenito, and M.F. Green Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis Schizophr. Res. 53 2002 27
15. J.T. Coull Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition Drugs Aging 5 1994 116 126
16. J.M. Crook, E. Tomaskovic-Crook, D.L. Copolov, and B. Dean Low muscarinic receptor binding in prefrontal cortex from subject with schizophrenia: a study of broadmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment Am. J. Psychiatry 158 2001 918 925
17. D.G. Daniel, T.E. Goldberg, D.R. Weinberger, J.E. Kleinman, D. Pickar, L.J. Lubick, and T.S. Williams Different side-effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study Am. J. Psychiatry 153 1996 417 419
18. D.C. Delis, J.H. Kramer, E. Kaplan, and B.A. Ober The California verbal learning test (CVLT) 1987 Psychological San Antonio, TX
19. 2 dopamine receptor binding in the living human brain by PET Science 231 1986 258 261
20. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch. Gen. Psychiatry 49 1992 538 544
21. 2 receptors from plasma levels: a PET imaging Schizophr. Res. 36 1999 220
22. R. Freedman, C.E. Adams, and S. Leonard The alpha7-nicotinic acethylcholine receptor and the pathology of hippocampal interneurons in schizophrenia J. Chem. Neuroanat. 2 2000 299 306
23. J.I. Friedman, D.N. Adler, E. Howanitz, P.D. Harvey, G. Brenner, H. Temporini, L. White, M. Parrella, and K.L. Davis A double-blind placebo-controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia Biol. Psychiatry 5 2002 349 357
24. J.I. Friedman, D.G. Stewart, and J.M. Gorman Potential noradrenergic targets for cognitive enhancement in schizophrenia CNS Spectr. 9 2004 350 355
25. D.E.M. Fujii, I. Ahmed, M. Jokumsen, and J.M. Compton The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients J. Neuropsychiatry Clin. Neurosci. 9 1997 240 245
26. C.A. Galletly, R. Clark, A.C. McFarlane, and D.L. Weber Relationship between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine Psychiatry Res. 72 1997 161 166
27. R. Ganguli, F. Reynolds, and D.J. Kupfer Electroencephalographic sleep in young never-medicated schizophrenics Arch. Gen. Psychiatry 44 1987 36 44
28. T.P. George, C.D. Verrico, M.R. Picciotto, and R.H. Roth Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization J. Pharmacol. Exp. Ther. 295 2000 58 66
29. D.C. German, K.F. Manaye, D. Wu, L.B. Hersh, and R.M. Zweig Mesopontine cholinergic and non-cholinergic neurons in schizophrenia Neuroscience 94 1999 33 38
30. E. Giacobini Cholinesterase inhibitors stabilize Alzheimer's disease Ann. N.Y. Acad. Sci. 920 2000 321 327
31. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am. J. Psychiatry 158 2001 1367 1377
32. T.E. Goldberg, E.F. Torrey, J.M. Gold, and J.D. Raggland Learning and memory in monozygotic twins discordant for schizophrenia Psychol. Med. 23 1993 71 85
33. T.E. Goldberg, R.D. Greenberg, S.J. Griffin, J.M. Gold, J.E. Kleinman, D. Pickar, S.C. Schulz, and D.R. Weinberger The effects of clozapine on cognition and psychiatric symptoms in patients with schizophrenia Br. J. Psychiatry 162 1993 43 48
34. C.J. Golden Stroop color and word test: manual for clinical and experimental uses 1978 Stoelting Chicago
35. E. Gould Serotonin and hippocampla neurogenesis Neuropsychopharmacology 21 Suppl. 2 1999 45S 51S
36. J. Grace, S.B. Bellus, M.L. Raulin, M.I. Herz, B.L. Priest, V. Brenner, K. Donnelly, P. Smith, and S. Gunn Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning Psychiatr. Serv. 47 1996 41 45
37. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153 1996 321 330
38. M.F. Green Schizophrenia from a neurocognitive perspective Probing the impenerable darkness 1998 Allyn and Bacon Boston, MA
39. M. Green, and E. Walker Attentional performance in positive- and negative-symptom schizophrenia J. Ment. Nerv. Disord. 174 1986 208 213
40. M.F. Green, B.D. Marshall, W.C. Wirshing, D. Ames, S. McGurk, R.S. Kern, and J. Mintz Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry 154 1997 799 804
41. M.F. Green, R.S. Kern, D.L. Braff, and J. Mintz Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr. Bull. 26 2000 119 136
42. M.F. Green, K.H. Nuechterlein, J.M. Gold, D.M. Barch, J. Cohen, S. Essock, W.S. Fenton, F. Frese, T.E. Goldberg, R.K. Heaton, R.S. Keefe, R.S. Kern, H. Kraemer, E. Stover, D.R. Weinberger, S. Zalcman, and S.R. Marder Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria Biol. Psychiatry 56 5 2004 301 307
43. C. Hagger, P. Buckley, J.T. Kenny, L. Friedman, D. Ubogy, and H.Y. Meltzer Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schziophrenic patients receiving clozapine Biol. Psychiatry 34 1993 702 712
44. P.D. Harvey, and R.S. Keefe Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment Am. J. Psychiatry 158 2001 176 184
45. P.D. Harvey, D. Sukhodolsky, M. Parrella, L. White, and M. Davidson The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients Schizophr. Res. 27 1997 211 218
46. R.K. Heaton Wisconsin card sorting test manual 1981 Psychological Assessment Resources Odessa, FL
47. R.W. Heinrichs, and K.K. Zakzanis Neurocognitive deficit in schizophrenia: a quantitative review of the evidence Neuropsychology 12 1998 426 445
48. J.A. Hobson The dreaming brain 1988 Basics Books New York
49. E. Holsboer-Trachsler, M. Hatzinger, R. Stohler, U. Hemmeter, J. Gray, J. Muller, R. Kocher, and R. Spiegel Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man Neuropsychopharmacology 8 1993 87 92
50. D.J. Holt, M.M. Herman, T.M. Hyde, J.E. Kleinman, S.M. Sinton, D.C. German, L.B. Hersh, A.M. Graybiel, and C.B. Saper Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia Neuroscience 94 1999 21 31
51. M. Hussain, Z. Chaudhry, and S. Hussain Rivastigmine tartrate in treatment of neocognitive deficits in clozapine treated schizophrenics 51th Annual Meeting of Canadian Psychiatric Association Book of Abstracts 2001 CPA 64
52. J. Ichikawa, J. Dai, and H.Y. Meltzer 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex J. Brain Res. 939 2001 34 42
53. S. Jordan, V. Koprivica, R. Chen, K. Tottori, T. Kikuchi, and C.A. Altar The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor Eur. J. Pharmacol. 441 2002 137 140
54. J.M. Kane, G. Honigfeld, J. Singer, and H. Meltzer Clozapine in treatment-resistant schizophrenics Psychopharmacol. Bull. 24 1988 62 67
55. S. Kapur, and P. Seeman Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action J. Psychiatry Neurosci. 25 2000 161 166
56. C.N. Karson, M.F. Casanova, J.E. Kleinman, and W.S. Griffin Choline acetyltransferase in schizophrenia Am. J. Psychiatry 150 1993 454 459
57. C.N. Karson, R.E. Mrak, M.M. Husain, and W.S. Griffin Decreased mesopontine choline acetyltransferase levels in schizophrenia Mol. Chem. Neuropathol. 29 1996 181 191
58. A.S. Kaufman, and E.O. Lichtenberger Essentials of WAIS-III assessment 1998 John Wiley & Sons New York
59. R.S. Keefe, S.G. Silva, D.O. Perkins, and J.A. Lieberman The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis Schizophr. Bull. 25 1999 201 222
60. R.S. Keefe, L.J. Seidman, B.K. Christensen, R.M. Hamer, T. Sharma, and M.M. Sitskoorn Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol Am. J. Psychiatry 161 2004 985 995
61. J.S. Kennedy, R.J. Polinsky, B. Jonhson, P. Loosen, A. Enz, R. Laplanche, D. Schmidt, L.C. Mancione, W.C. Parris, and M.H. Ebert Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans J. Clin. Psychopharmacol. 19 1999 513 521
62. R.S. Kern, M.F. Green, B.D. Marshall Jr., W.C. Wirshing, D. Wirshing, S. McGurk, S.R. Marder, and J. Mintz Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients Biol. Psychiatry 44 1998 726 732
63. M.S. Keshavan, C.F. Reynolds, and J. Brar Sleep EEG changes in schizophrenia during haloperidol treatment Biol. Psychiatry 25 1989 181A
64. M.S. Keshavan, S.P. Mahadik, C.F. Reynolds III, S. Mukerjee, A. Korenovsky, P. Houck, and D.B. Jarrett Plasma cholinesterase isozymes and REM latency in schizophrenia Psychiatry Res. 43 1992 23 29
65. D.J. King Psychomotor impairment and cognitive disturbances induced by neuroleptics Acta Psychiatr. Scand. 380 1994 53 58
66. R.M. Kirrane, V. Mitroupoulou, M. Nunn, J. Silverman, and L.J. Siever Physostigmine and cognition in schizotypal personality disorder Schizophr. Res. 48 2001 1 5
67. J.H. Krystal, D.C. D'souza, I.L. Petrakis, A. Belger, R. Berman, D.S. Charney, W. Abi-Saab, and S. Madonick NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies for neuropsychiatric disorders Harv. Rev. Psychiatry 7 1999 125 133
68. T. Kuroki, H.Y. Meltzer, and J. Ichikawa Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens J. Pharmacol. Exp. Ther. 288 1999 772 781
69. I.C. Lai, C.J. Hong, and S.J. Tsai Association study of a nicotinic receptor variant with schizophrenia disorders Neuropsychobiology 43 2001 15 18
70. M.A. Lee, P.A. Thompson, and H.Y. Meltzer Effects of clozapine on cognitive function in schizophrenia J. Clin. Psychiatry 55 1994 B82 B87 (Suppl.)
71. A. Lenzi, E. Maltinti, E. Poggi, L. Fabrizio, and E. Coli Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia Clin. Neuropharmacol. 26 6 2003 317 321
72. M.D. Lezak Neuropsychological assessment 2 ed. 1983 Oxford University Press New York
73. J.F. Liegeois, J. Bruhwyler, J.C. Hendrick, J. Delarge, J.J. Legros, and J. Damas Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats Neurosci. Lett. 319 2002 49 52
74. J.P. Lindenmayer, A. Iskander, M. Park, F.S. Apergi, P. Czobor, R. Smith, and D. Allen Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study J. Clin. Psychiatry 59 1998 521 527
75. S.K. Liu, W.J. Chen, C.J. Chang, and H.N. Lin Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol Neuropsychopharmacology 22 2000 311 319
76. G.W. MacEwan, T.S. Ehmann, I. Khanbhai, and C. Wrixon Donepezil in schizophrenia is it helpful? An experimental design case study Acta Psychiatr. Scand. 104 2001 469 472
77. T.C. Manschreck, D.A. Redmond, S.F. Candela, and B.A. Maher Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia J. Neuropsychiatry Clin. Neurosci. 11 1999 481 489
78. S.R. McGurk, and H.Y. Meltzer The role of cognition in vocational functioning in schizophrenia Schizophr. Res. 45 2000 175 184
79. H.Y. Meltzer Presynaptic receptors. Relevance to psychotropic drug action in man Ann. N. Y. Acad. Sci. 604 1990 353 371
80. A. Mendrek, K.R. Laurens, K.A. Kiehl, E.T. Ngan, E. Stip, and P.F. Liddle Changes in distributed neural circuitry function in patients with first-episode schizophrenia Br. J. Psychiatry 185 2004 205 214
81. B. Moghaddam, B. Adams, A. Verma, and D. Daly Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J. Neurosci. 17 1997 2921 2927
82. K.H. Nuechterlein, and M.E. Dawson Information processing and attention in the development of schizophrenia disorders Schizophr. Bull. 10 1984 160 203
83. V. O'keane, K. Abel, and R.M. Murray Growth hormone responses to pyridostigmine in schizophrenia: evidence for cholinergic dysfunction Biol. Psychiatry 36 1994 582 588
84. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch. Gen. Psychiatry 52 1995 998 1007
85. T.F. Oltmanns Selective attention in schizophrenic and manic psychoses: the effect of distraction in information processing J. Abnorm. Psychology 87 1978 212 225
86. T.F. Oltmanns, and J.M. Neale Schizophrenic performance when distractors are present: attentional deficit or differential task difficulty J. Abnorm. Psychology 84 1975 205 209
87. F. Paquet, J.P. Soucy, E. Stip, M. Levesque, A. Elie, and M.A. Bedard Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia J. Neuropsychiatry Clin. Neurosci. 16 1 2004 47 56
88. S.G.F. Potkin Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics J. Clin. Psychopharmacol. 21 2001 479 483
89. S.E. Purdon Cognitive improvement in schizophrenia with novel antipsychotic medications Schizophr. Res. 35 1999 S51 S60 (Suppl.)
90. S.E. Purdon, B.D. Jones, E. Stip, A. Labelle, D. Addington, S.R. David, A. Breier, G.D. Tollefson The Canadian Collaborative Group for research in schizophrenia Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol Arch. Gen. Psychiatry 57 2000 249 258
91. S.E. Purdon, A. Labelle, and L.J. Boulay Neuropsychological change in schizophrenia after six weeks of clozapine Schizophr. Res. 48 2001 57 67
92. S.E. Purdon, A. Malla, and W. Lit Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol J. Psychiatry Neurosci. 26 2001 137 149
93. S.E. Purdon, N. Woodward, and S.R. Lindborg Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol Psychopharmacology 169 2003 390 397
94. A. Raine, D. Benishay, T. Lencz, and A. Scarpa Abnormal orienting in schizotypal personality disorder Schizophr. Bull. 23 1997 75 82
95. D. Riemann, F. Hohagen, S. Krieger, H. Gann, W.E. Müller, R. Olbrich, H.J. Wark, M. Bohus, H. Low, and M. Berger Cholinergic REM induction test: muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia J. Psychiatr. Res. 28 1994 195 210
96. G.S. Robertson, and H.C. Fibiger Effects of olanzapine on regional C-Fos expression in rat forebrain Neuropsychopharmacology 14 1996 105 110
97. A. Rossi, F. Mancini, P. Stratta, P. Mattei, R. Gismondi, F. Pozzi, and M. Casacchia Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study Acta Psychiatr. Scand. 95 1997 40 43
98. D. Saffer, M. Metcalfe, and A. Coppen Abnormal dexamethasone suppression test in type II schizophrenia Br. J. Psychiatry 147 1985 721 723
99. K.W. Sax, S.M. Strakowski, and P.E. Keck Jr. Attentional improvement following quetiapine fumarate treatment in schizophrenia Schizophr. Res. 33 1998 151 155
100. H. Scherer, E. Stip, F. Paquet, and M.A. Bedard Mild procedural learning disturbances in neuroleptic-naive patients with schizophrenia J. Neuropsychiatry Clin. Neurosci. 15 2003 58 63
101. A. Schotte, P. Bonaventure, P.F. Janssen, and J.E. Leysen In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used Jpn. J. Pharmacol. 6 1995 399 412
102. M. Schredl, B. Weber, D. Braus, and I. Heuser The effect of rivastigmine on sleep in elderly healthy subjects Exp. Gerontol. 35 2000 243 249
103. T. Sharma, and P.D. Harvey Cognitive deficits in schizophrenia 2000 Oxford University Press Oxford
104. T. Sharma, and P. Harvey Cognitive enhancement as a treatment strategy in schizophrenia T. Sharma P. Harvey Cognition in schizophrenia, impairments, importance and treatment strategies 2000 Oxford University Press Oxford 286 302
105. T. Sharma, and D.D. Mockler The cognitive efficacy of atypical antipsychotics in schizophrenia J. Clin. Psychopharmacol. 18 1998 12S 19S
106. S. Shirazi-Southall, D.E. Rodriguez, and G.G. Nomikos Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat Neuropsychopharmacology 26 2002 583 594
107. R.C.I. Smith The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia Int. J. Neuropsychopharmacol. 4 2001 239 250
108. O. Spreen, and E. Strauss A compendium of neuropsychological tests: administration, norms, and commentary 1991 Oxford University Press New York
109. E. Stip Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics J. Psychiatry Neurosci. 25 2000 137 153
110. E. Stip Olanzapine and cognition P.V. Tran F.P. Bymaster N.C. Tye Olanzapine: a novel antipsychotic 2000 Lippincott Williams & Williams Healthcare Philadelphia 401 415
111. E. Stip, and I. Lussier The effect of risperidone on cognition in patients with schizophrenia Can. J. Psychiatry 41 1996 S35 S40 (Suppl.)
112. E. Stip, G. Remington, S.M. Dursun, J.P. Reiss, E. Rotstein, G.W. MacEwan, P.R. Chokka, B. Jones, R.A. Dickson and the Canadian switch study group A Canadian multi-center trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine J. Clin. Psychopharmacol. 23 2003 400 404
113. E. Stip, S. Chouinard, P. Lalonde, G. Zahirney, A.L. Bentaleb, J.P. Melun, J. Poulin, H. Cohen, F. Guillem, and R. Godbout Effects on positive symptoms and tolerability of rivastigmine in patients with schizophrenia and cognitive impairment Schizophr. Res. 67 2004 151
114. R. Tandon Effects of atypical antipsychotics on polysomnographic measures in schizophrenia L.L. Judd B. Saletu V. Filip Basic and clinical science of mental and addictive disorders 1997 Krager Basel
115. R. Tandon, and J.F. Greden Cholinergic hyperactivity and negative schizophrenic symptoms: a model of cholinergic/dopaminergic interactions in schizophrenia Arch. Gen. Psychiatry 46 1989 745 753
116. R. Tandon, J.E. Shipley, J.F. Greden, N.A. Mann, W.H. Eisner, and J.A. Goodson Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms Schizophr. Res. 4 1991 23 30
117. R. Tandon, J.R. DeQuardo, J. Goodson, N.A. Mann, and J.F. Greden Effect of anticholinergics on positive and negative symptoms in schizophrenia Psychopharmacol. Bull. 28 1992 297 302
118. R. Tandon, J.E. Shipley, S. Taylor, and J.F. Greden Sleep abnormalities in schizophrenia: cholinergic contribution Clin. Neuropharmacol. 15 Suppl. 1 1992 294A 295A
119. G.D. Tollefson Cognitive function in schizophrenic patients J. Clin. Psychiatry 57 1996 31 39
120. G. Tsai, P. Yang, L.C. Chung, N. Lange, and J. Coyle d-serine added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 44 1998 1081 1089
121. D.P. Van Kammen, W.B. Van Kammen, J. Peters, K. Goetz, and T. Neylan Decreased slow-wave sleep and enlarged lateral ventricles in schizophrenia Neuropsychopharmacology 1 1988 265 271
122. J.M. Van Rossum The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs Arch. Int. Pharmacodyn. 160 1966 492 494
123. D.I. Velligan, J. Newcomer, J. Pultz, J. Csernansky, A.L. Hoff, R. Mahurin, and A.L. Miller Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr. Res. 53 2002 239 248
124. L.N. Voruganti, R.J. Heslegrave, and A.G. Awad Neurocognitive correlates of positive and negative syndromes in schizophrenia Can. J. Psychiatry 42 1997 1066 1071
125. D. Wechsler WAIS-R manual 1981 Psychological San Antonio, TX
126. T. Yoshino, K. Nisijima, S. Katoh, K. Yui, and M. Nakamura Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex Neurochem. Int. 40 4 2002 355 360
127. T.P. Zahn, D. Pickar, and R.J. Haier Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia Schizophr. Res. 13 1994 133 144